SCHEMBL9133379

SCHEMBL9133379

O=C(O)NNc1nc2ccccc2s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 9/20 0.74
▸ CYP1A2 P05177 3/20 0.74
▸ MAPT P10636 7/20 0.71
▸ NPC1 O15118 6/20 0.71
▸ RAB9A P51151 6/20 0.71
▸ SMN1; SMN2 Q16637 5/20 0.71
▸ HPGD P15428 1/20 0.71
▸ ALDH1A1 P00352 3/20 0.68
▸ CYP2C19 P33261 2/20 0.67
▸ KDM4E B2RXH2 2/20 0.63
▸ LMNA P02545 1/20 0.63
▸ CYP2C9 P11712 1/20 0.63
▸ HTT P42858 1/20 0.63
▸ GFER P55789 1/20 0.63
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ ADORA1 P30542 1/20 0.59
▸ DYRK1A Q13627 1/20 0.59
▸ NFKB1 P19838 2/20 0.59
▸ NFKB2 Q00653 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314994 0.86 KDM4E (0.80) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL1580942 0.83 NPC1 (0.73) GAAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL27692836 0.82 GAA (0.68) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL11745024 0.81 GAA (0.67) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL8729336 0.79 NPC1 (0.63) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL30598987 0.78 KDM4E (0.76) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL26115749 0.78 KDM4E (0.76) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL11712929 0.78 NPC1 (0.73) GAAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2245547 0.77 NPC1 (0.71) GAACYP1A2MAPTNPC1RAB9A
SCHEMBL32674581 0.77 NPC1 (0.84) GAAMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5411967-A Antiinflammatory, immunosuppressant, antitumor AMERICAN HOME PRODUCTS CORPORATION (US) 1995-05-02 — — US claimed
CN-101959516-B Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2013-05-08 — — CN disclosed
CN-101959516-A Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2011-01-26 — — CN disclosed
US-5411967-A Antiinflammatory, immunosuppressant, antitumor AMERICAN HOME PRODUCTS CORPORATION (US) 1995-05-02 — — US disclosed
Send feedback